Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. (15th March 2015)

• Record Type: Journal Article
• Authors: Bilen, Mehmet Asim; Lin, Sue-Hwa; Tang, Dean G.; Parikh, Kinjal; Lee, Mong-Hong; Yeung, Sai-Ching J.; Tu, Shi-Ming
• Other Names: Mauri Francesco A. Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2015(2015)
• Publication Date: 2015-03-15
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2015/471861
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Metformin is derived from galegine, a natural ingredient, and recent studies have suggested that metformin could enhance the antitumor effects of hormone ablative therapy or chemotherapy and reduce prostate cancer-specific mortality. Zyflamend is a combination of herbal extracts that reduces inflammation and comprises turmeric, holy basil, green tea, oregano, ginger, rosemary, Chinese goldthread, hu zhang, barberry, and basil skullcap. We propose a maintenance regimen with metformin and/or Zyflamend that targets cancer stem cells and the tumor microenvironment to keep the cancer dormant and prevent it from activation from dormancy. Herein, we report the clinical course of four patients who experienced a clinical response after treatment with metformin and/or Zyflamend.